Radiomics analysis to predict pulmonary nodule malignancy using machine learning approaches

Matthew T. Warkentin^{1,2} Hamad Al-Sawaihey¹ Stephen Lam 3,4 Geoffrey Liu ^{2,5} Brenda Diergaarde ⁶ Jian-Min Yuan ⁶ David O. Wilson⁷ Martin C. Tammemägi⁸ Sukhinder Atkar-Khattra 3,4 Benjamin Grant⁵ Yonathan Brhane¹ Elham Khodayari-Moez¹ Kieran R. Campbell ^{1,9,10,11,12,13} Raviean J. Hung $1,2$

Affiliations:

- 1. Prosserman Center for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada
- 2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 3. Department of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- 4. British Columbia Cancer Agency, Vancouver, BC, Canada
- 5. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

- 6. Department of Human Genetics and UPMC Hillman Cancer Center, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
- 7. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 8. Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada
- 9. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
- 10. Department of Statistical Sciences, University of Toronto, Toronto, ON, Canada
- 11. Department of Computer Science, University of Toronto, Toronto, ON, Canada
- 12. Ontario Institute of Cancer Research, Toronto, ON, Canada
- 13. Vector Institute, Toronto, ON, Canada

Corresponding Author: **Rayjean J. Hung** [\(rayjean.hung@lunenfeld.ca\)](mailto:rayjean.hung@lunenfeld.ca)

Abstract ¹

Purpose ²

Screening with low-dose computed tomography can reduce lung cancer-related mortality. $\frac{3}{3}$ However, most screen-detected pulmonary abnormalities do not develop into cancer $\frac{4}{4}$ and it remains challenging to identify high-risk nodules among those with indeterminate $\frac{1}{5}$ appearance. We aim to develop and validate prediction models to discriminate between ϵ benign and malignant pulmonary lesions based on radiological features.

Methods ⁸

Using four international lung cancer screening studies, we extracted 2,060 radiomic 9 features for each of 16,797 nodules among 6,865 participants. After filtering out $_{10}$ redundant and low-quality radiomic features, 642 radiomic and 9 epidemiologic features $_{11}$ remained for model development. We used cross-validation and grid search to assess $_{12}$ three machine learning models (XGBoost, Random Forest, LASSO) for their ability to $_{13}$ accurately predict risk of malignancy for pulmonary nodules. We fit the top-performing $_{14}$ ML model in the full training set. We report model performance based on the area under $_{15}$ the curve (AUC) and calibration metrics in the held-out test set. 16

Results 17

The ML models that yielded the best predictive performance in cross-validation were $_{18}$ XGBoost and LASSO, and among these models, LASSO had superior model calibration, $_{19}$ which we considered to be the optimal model. We fit the final LASSO model based $_{20}$ on the optimized hyperparameter from cross-validation. Our radiomics model was both $_{21}$ well-calibrated and had a test-set AUC of 0.930 (95% CI: 0.901-0.957) and out-performed $_{22}$ the established Brock model (AUC=0.868, 95% CI: 0.847-0.888) for nodule assessment. 23

Conclusion

We developed highly-accurate machine learning models based on radiomic and 25 epidemiologic features from four international lung cancer screening studies that may be 26 suitable for assessing suspicious, but indeterminate, screen-detected pulmonary nodules ₂₇ for risk of malignancy.

Introduction ²⁹

Lung cancer is the leading cause of cancer mortality globally^{[1](#page-18-0)}. Only 10-20% lung cancer so patients live up to five years after diagnosis^{[2](#page-18-1)}. However, several large randomized $\frac{31}{2}$ screening trials have demonstrated that low-dose computed tomography (CT) screening 32 can significantly reduce lung cancer mortality through early detection^{[3–](#page-18-2)[6](#page-18-3)}. The National 33 Lung Screening Trial (NLST) observed a 20% reduction in lung cancer-related mortality $_{34}$ following CT screening^{[4](#page-18-4)}, while the Dutch-Belgian trial (NELSON) observed a reduction in $_{\tiny \rm 35}$ mortality of 24% in men and [3](#page-18-2)3% in women³. . **36 . 36**

Despite the promise of screening, the clinical management of screen-detected pulmonary 37 nodules and the false-positive rate are important determinants for screening program ₃₈ efficacy. Across several studies, the average nodule detection rate was 20%, meanwhile, 39 more than 90% of screen-detected nodules were benign^{[7](#page-18-5)}. Inaccurate assessment \Box 40 of indeterminate nodules may lead to unnecessary diagnostic workup, including 41 diagnostic screens (which confer higher radiation dosing), invasive procedures such as 42 bronchoscopy, biopsy, or surgery, and may lead to overdiagnosis of indolent cancers^{[7](#page-18-5)}. 43 Excess follow-up carries significant healthcare costs, utilizes critical hospital and human 44 resources, and may lead to adverse events and complications, including death, and can 45 cause anxiety and decreased quality of life for the screened participant. ⁴⁶

Several guidelines have been developed to help inform indeterminate nodule 47 management, however, there remains significant heterogeneity in these recommendations^{[8](#page-18-6)} $rac{2}{48}$. To address these issues, probability models have been developed to help identify high-risk $_{49}$ lesions and guide clinical decision-making $23-25$ $23-25$ $23-25$. These models have traditionally been 50 based on patient characteristics (e.g., age, smoking history, etc.) and clinically-collected $\frac{51}{12}$ nodule morphology and textural features (e.g., size, attenuation, etc.). These features $_{52}$ characterize important aspects of the nodule and are routinely collected as part of the 53

clinical management of pulmonary findings. The state of the state of 54

Nodule probability models based on routinely-collected patient and nodule information 55 have shown good performance, however, there is growing interest in leveraging $_{56}$ medical images directly to perform automated quantitative image analysis, enabling 57 the quantification of hundreds or thousands of radiomic features that may capture $\frac{58}{18}$ important information otherwise imperceptible to the human eye. Radiomic features $\frac{59}{2}$ quantify aspects of the 3-dimensional (3D) morphology and grayscale distribution for a 60 region-of-interest^{[26](#page-20-3)}. It is expected that radiomic features, in combination with patient-level ϵ_{61} information, will be able to accurately discriminate between benign and malignant pulmonary nodules beyond what has been achieved with traditional clinical features. However, it is currently unknown which features will be most important and whether they 64 will generalize well to other screening populations. The state of the state of $\frac{65}{65}$

The goal of the current study is to perform quantitative image analysis and evaluate the predictive performance of high-dimensional radiomic features for pulmonary nodule ⁶⁷ malignancy assessment, and to develop and validate models using data from several 68 large independent international lung cancer screening studies.

Methods ⁷⁰

Lung Cancer Screening Studies 71

As part of the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) $_{72}$ program, we used data collected by four independent lung cancer screening studies for $\frac{73}{2}$ this analysis: 1. National Lung Screening Trial (NLST), 2. PanCanadian Early Detection $_{74}$ of Lung Cancer (PanCan) Study, 3. International Early Lung Cancer Action Program ₇₅ (IELCAP-Toronto), and 4. Pittsburgh Lung Screening Study (PLuSS). Details of each τ_6 study have been described previously^{[4,](#page-18-4) [5](#page-18-7), [27](#page-20-4)–[30](#page-20-5)}. We provide brief descriptions of each π study in the following sections. Details about the study protocol used by each study are $\frac{78}{18}$ included in the Supplemental Materials. The state of the state of

National Lung Screening Trial (NLST) ⁸⁰

NLST was a large randomized multi-center lung cancer screening study comparing $_{81}$ low-dose helical CT to standard chest radiography (CXR) for screening adult heavy 82 smokers^{[4,](#page-18-4) [5](#page-18-7)}. Eligible participants were age 55 to 74 years, with 30 or more pack-years sa history of smoking, and former smokers quitting no more than 15 years prior. NLST $_{84}$ enrolled 53,456 participants across 33 centers in the United States in 2002. We only use 85 image data from the CT screening arm in the current study. Positive screen-detected $_{86}$ findings were considered as any non-calcified nodules (NCN) with a diameter of 4mm or σ_{B7} greater. And the set of the set of

Pan-Canadian Early Detection of Lung Cancer Study (PanCan) ⁸⁹

PanCan was a multi-center, single-arm prospective lung cancer screening study that \Box included 2,537 participants^{[27](#page-20-4)}. Participants were recruited from eight sites across Canada. $_{91}$ Eligible participants included those 50 to 75 years of age, without a self-reported history of $_{92}$

lung cancer, current or former smokers, an estimated 6-year risk of lung cancer of at least $_{93}$ 2% based on an earlier edition of the PLCOm2012 model^{[31](#page-20-6)}, and an ECOG performance $_{94}$ status of 0 or 1. Screening was performed with multi-detector row CT scanners. Each scan was reviewed by a train radiologist and up to 10 lung nodules were identified and $_{96}$ recorded. The contract of the

International Early Lung Cancer Action Program (IELCAP-Toronto) $\frac{98}{98}$

IELCAP was an international single-arm multi-centre study evaluating low-dose CT ₉₉ for lung cancer screening of high-risk individuals^{[28,](#page-20-7) [29](#page-20-8)}. A common study protocol was $_{100}$ adopted for screening regimen, however, each site were able to make decisions regarding $_{101}$ enrollment criteria. The Toronto location (hereafter referred to as IELCAP-Toronto), was ₁₀₂ based out of Princess Margaret Cancer Centre and began in 2003. IELCAP-Toronto 103 enrolled 4,782 adults age 50 or older who were ever-smokers with more than 104 10 pack-years history of smoking. Participants were screened at baseline with ¹⁰⁵ milt-detector-row CT scanners. Positive findings were considered as any NCN found on 106 a baseline scan. 107

Pittsburgh Lung Screening Study (PLuSS) ¹⁰⁸

PLuSS was a lung cancer screening trial that recruited 3,642 eligible participants between January 2002 and April 2005 30 . Eligible participants included those age 50 to $_{110}$ 79 years, with no personal history of lung cancer, no concurrent participation in other $_{111}$ lung screening studies, no chest CT within the preceding year, current or former smoker $_{112}$ with 0.5 pack-years history of smoking for at least 25 years, no smoking cessation within $_{113}$ 10 years of enrollment, and body weight less than 400 pounds. Participants underwent $_{114}$ lose-dose chest CT at baseline. Positive findings were considered as any NCN.

Pulmonary Nodule Segmentation 116

We performed supervised, semi-automated segmentation of screen-detected pulmonary 117 nodules using the open-source 3D Slicer software^{[32](#page-20-9)} and the Chest Imaging Platform $_{118}$ extension^{[33](#page-21-0), [34](#page-21-1)}. Our radiologist (HAS) located and reviewed each pulmonary lesion. 119 Upon locating the lesion, the radiologist placed a seed-point at the approximate centroid $_{120}$ of the lesion; semi-automated segmentation was performed based on the single seed-point, and manual touch-ups were performed at the discretion of the radiologist $_{122}$ to fix over- or under-segmentation. All nodules were reviewed using standard lung 123 windows. Segmentations for PanCan were performed by the PanCan investigators $_{124}$ using an automated segmentation algorithm based on a commercial software and $_{125}$ images and masks were provided without further processing, except those relevant $_{126}$ to the feature extraction, detailed in the following section. We also collected detailed $_{127}$ nodule information, including: lung and lobe location, suspicion of nodule malignancy, a_{128} nodule-specific LungRADS score (based on LungRADS 1.1, 8 8 8), and ratings for semantic ${}_{129}$ nodule features including: margin, sphericity, subtlety, spiculation, solidity, calcification, 130 structure, and lobulation. Details on the ratings systems for semantic nodule features are $_{131}$ described in **Supplementary Table 1**.

Radiomics Feature Extraction 133

We performed radiomic feature extraction for baseline screen-detected pulmonary 134 nodules using PyRadiomics (version 3.0.1)^{[26](#page-20-3)}. Due to heterogeneity in image acquisition $_{135}$ settings between and within screening studies, all images and masks were resampled 136 and interpolated to have unit voxel spacing (i.e., isotropy). We used a linear interpolator $_{137}$ for images and nearest-neighbours interpolator for masks (to preserve labels). Grayscale ₁₃₈ intensities were discretized into bins using a bin width of 25 for histogram-based features. 139 Voxel intensities were right-shifted by 1000 units prior to feature extraction to avoid 140

negative values during feature computations. The state of the stat

Feature classes and the number of features per class were: (1) first-order statistics $_{142}$ [18 features], (2) shape-based [14 features], (3) gray level coocurrence matrix $[24]$ $_{143}$ features], (4) gray level run length matrix [16 features], (5) gray level size zone matrix $_{144}$ [16 features], (6) neighbouring gray tone difference matrix [5 features], and (7) gray level $_{145}$ dependence matrix [14 features]. The list of radiomic features for each class is provided $_{146}$ in **Supplemental Table 2**. We extracted shape and intensity-based features using the 147 original image. We also extracted intensity-based features from images after applying $_{148}$ several transformations, including: wavelet, Laplacian of Gaussian (LoG), Square, ¹⁴⁹ SquareRoot, Logarithm, Exponential, Gradient, and LocalBinaryPattern3D. In total, we 150 extracted 2,060 radiomic features per nodule. 151

Statistical Analysis 152

Epidemiologic covariates and outcomes 153

Epidemiologic data were harmonized across the four screening studies to establish a $_{154}$ common set of patient-level covariates. After harmonization, age, sex, family history 155 of lung cancer among a first-degree relative, history of COPD or emphysema, smoking ¹⁵⁶ status, smoking duration, smoking intensity, years since quitting, and body mass index 157 were included. We combined epidemiologic and radiomic features from the four screening $_{158}$ studies to form our candidate predictor set. Nodule malignancy status was the outcome ₁₅₉ of interest and was determined based on the nodule-specific radiological assessment $_{160}$ described in the Supplemental Methods.

Model Development 162

We used subject-level random sampling to split the data into training $(80%)$ and testing $_{163}$ $(20%)$ sets, ensuring all nodules for a specific participant were in the same split. The $_{164}$

training set was further split into five folds using subject-level random sampling to 165 perform cross-validation. We had 2,060 radiomic features to assess for their ability 166 to classify benign and malignant pulmonary nodules. Many radiomic features have $_{167}$ correspondences to established clinically-collected (i.e., semantic) nodules features, ¹⁶⁸ however, many features have an unknown predictive value. We performed an initial set of 169 filtering steps to remove zero variance ($n=78$), low quality ($n=11$), and weakly predictive 170 (FDR-adjusted P-value > 0.05 in univariate models, $n=248$), and highly-redundant 171 features (pairwise correlation > 0.9 , n=1,081), described in detail in the Supplemental $_{172}$ $\mathsf{Methods.} \hspace{4cm} \color{red} \blacksquare$

Using the 9 epidemiologic covariates and 647 radiomic features retained after filtering, 174 we performed cross-validation to identify the top-performing ML model. All predictors 175 were normalized prior to model fitting. We assessed the following ML models: penalized logistic regression (LASSO), Random Forest (RF), and Gradient Boosted Trees (XGBoost). We first performed grid-search over a set of hyperparameters chosen using 178 a Latin hypercube space-filling design^{[35](#page-21-2)}. We then performed random grid search over a 179 finer set of hyperparameters for the top-performing model. The optimal hyperparameter(s) $_{180}$ were then fit to the full training set and model performance was evaluated in the hold-out $_{181}$ test set. A schematic of the analytic approach used in this study is presented in **Figure 1**. ¹⁸² All statistical analysis was performed using Python 3.7.10 and R 4.0.5 $^{36, 37}$ $^{36, 37}$ $^{36, 37}$ $^{36, 37}$ $^{36, 37}$. ¹⁸³

Model Performance ¹⁸⁴

We evaluated model performance in two complementary ways: (1) area under the receiver operating characteristic curve (AUC) to assess a models ability to assign higher risks to malignant lesions than to benign lesions (i.e., discrimination), and (2) compare model-estimated risks to observed risks (i.e., calibration). For calibration, we compared 188 predicted and observed risks within quantiles of predicted risks, and also assessed the ¹⁸⁹ ratio of expected to observed number of cancers and the difference between expected 190

and observed number of cancers. We report the AUC and calibration metrics with 191 percentile-based bootstrap confidence intervals. We compared our model against an 192 established nodule malignancy model (see Supplementary Materials for details).

Results 194

Basic demographics about the participants and nodules in the four lung cancer screening ₁₉₅ cohorts are presented in **Table 1**. Participants were similar in age between the cohorts. ¹⁹⁶ There were more men than women in NLST $(57\%$ vs. 43%), PanCan $(53\%$ vs. 47%), and $_{197}$ PLuSS (51% vs. 49%), while IELCAP-Toronto (61% vs. 39%) had more women. The four 198 cohorts had differing proportions of current and former smokers, and smoking histories 199 (i.e., duration, intensity, and years since quitting) varied between studies. All four cohorts $_{200}$ generally consisted of heavy current and former smokers. On average, PanCan had more ²⁰¹ nodules per participant, and smaller nodules, compared to the other studies.

We excluded 1,284 nodules from our study due technical issues with feature extraction, 203 2,574 nodules not first-appearing on baseline scans, and another 2,103 nodules due to ₂₀₄ missing patient-level data for the harmonized set of epidemiologic covariates. In total, we ²⁰⁵ had 16,797 baseline screen-detected nodules among 6,865 participants for our analytic ₂₀₆ sample. A complete flow chart for nodule inclusion in the analytic sample is presented in $_{207}$ **Supplemental Figure 1.** Distributional measures for the radiomic features based on the ₂₀₈ original CT image are presented in **Supplemental Table 4**. ²⁰⁹

We started with 2,060 radiomics features for model development. We removed 78 $_{210}$ features due to zero-variance and 11 features due to observed numerical instability (i.e., 211 implausible values) for a large number of participants. Next, we fit univariate models for $_{212}$ each feature in the training data, and retained features with a FDR-adjusted p-value less $_{213}$ than 0.05 ($n=248$). Lastly, we evaluated all pairwise sets of predictors with correlation $_{214}$ in the training set greater than 0.9 (in descending order) and removed the predictor with $_{215}$ the larger p-value. We retained 642 radiomic features for model development. More $_{216}$ details can be found in the Supplementary Materials and **Supplemental Figure 2**. The ²¹⁷ 642 radiomics features retained for model development are presented in **Supplemental** ²¹⁸

Table 4. We performed unsupervised clustering in the training data set using the 642 ₂₁₉ radiological features which revealed three distinct clusters of participants with similar ₂₂₀ radiomics profiles (see **Supplemental Figure 3**). We compared the three clusters based ₂₂₁ on their proportions of malignant pulmonary nodules and found statistically significant ₂₂₂ differences (P_{Exact} < 0.05).

We fit three different machine learning models (LASSO, XGBoost, Random Forest) 224 using 5-fold cross-validation based on the 642 radiomics features and 9 epidemiologic ₂₂₅ covariates. We first fit a coarse grid of 50 sets of hyperparameters for each ML model. ²²⁶ The results for this first-pass cross-validation are presented in **Table 2** and **Supplemental** ²²⁷ **Figure 4 and 5.** We selected the top performing model (LASSO) based on the 228 combination of discrimination (AUC) and calibration (calibration ratio) and performed a ₂₂₉ final cross-validation and grid search over a finer grid of hyperparameters. The optimal ₂₃₀ penalty value for the LASSO, based on CV, was used to fit the final model based on ²³¹ the full training data set, and predictions were made on the held-out test set to evaluate $\frac{232}{2}$ model performance. 233

The top ML submodels that yielded the highest cross-validated AUC were XGBoost ²³⁴ (AUC=0.933, 95% CI: 0.923-0.944), LASSO (AUC=0.930, 95% CI: 0.914-0.946), and ²³⁵ Random Forest (AUC=0.916, 95% CI: 0.904-0.929). However, calibration was superior ₂₃₆ for the LASSO model and was chosen as the top model (see **Supplemental Figure 6**). ²³⁷ In total, 142 predictors were retained in the final LASSO model with non-zero coefficients ₂₃₈ (See **Supplemental Figure 7**). ²³⁹

We compared our model with the established Brock Model. Our radiomics model had ₂₄₀ better discrimination, with a test-set AUC of 0.93 (95% CI: 0.90-0.96) compared to ₂₄₁ 0.87 (95% CI: 0.85-0.89) for the Brock Model (see **Figure 2**). Our model demonstrated ²⁴² excellent calibration when comparing observed risks with model-predicted (i.e., expected) ₂₄₃ risks, within quintiles of predicted risk. Our model had superior calibration compared $_{244}$

to the Brock Model (see **Supplemental Table 5** and **Supplemental Figure 8**). We ²⁴⁵ estimated the observed and expected number of malignant nodules (per 100,000) for the ₂₄₆ Brock model and our radiomics model. Our model had excellent calibration ratios (Exp / 247 Obs) of 1.02 (95% CI: 0.89-1.18) and calibration differences of 69.39 (95% CI: -399.67, ²⁴⁸ 507.94), versus 1.25 (95% CI: 1.15,1.36) and 1172.89 (95% CI: 774.17, 1583.65) for ²⁴⁹ the Brock Model, respectively. We compare clinically-relevant metrics (e.g., sensitivity, 250 specificity, etc.) between our model and the Brock model in Table 3. At nearly every ₂₅₁ probability threshold, our model has higher sensitivity, specificity, positive predictive value ₂₅₂ (PPV), negative predictive value (NPV), and accuracy, while identifying fewer lesions as $_{253}$ positive (i.e., suspicious), when compared to the Brock model. ²⁵⁴

Discussion ²⁵⁵

We developed and validated a pulmonary nodule malignancy assessment model based ₂₅₆ on radiomics and epidemiologic data from four large, international lung cancer screening ₂₅₇ cohorts using a machine learning approach. We found that the top-performing models ²⁵⁸ were based on gradient boosted trees (XGBoost) and penalized logistic regression $_{259}$

(LASSO), while the LASSO model provided the most optimal calibration. The use of $_{260}$ quantitative imaging features (i.e., radiomics) showed improved performance compared ²⁶¹ to an established model based primarily on semantic nodule features. Radiomic features ₂₆₂ have demonstrated value for their ability to predict nodule malignancy risk and may 263 improve the management of screen-detected pulmonary nodules by providing clinicians with supporting information for clinical decision-making.

Historically, the large quantity of medical images acquired during lung cancer ²⁶⁶ screening have been under-utilized for extracting important information to inform 267 nodule management. Traditionally, a modest set of semantic nodule traits are 268 qualitatively assessed by expert radiologists to provide a high-level characterization ²⁶⁹ of nodule morphology. High-throughput quantitative image analysis removes this ²⁷⁰ layer of inter-reader subjectivity, while also collecting many more features that may $_{271}$ further enhance our ability to characterize nodule morphology and intranodular textural $_{272}$ heterogeneity^{[38](#page-21-5)}. Radiomic features can describe various aspects of the nodule $_{273}$ morphology in ways that are imperceptible to the human eye (i.e., subtle intratumoral $_{274}$ textural changes)^{[26](#page-20-3)}. The combination of radiomic features with known important patient-level features are expected to improve clinical management of nodules. ²⁷⁶

Previous studies demonstrated that quantitative image analysis can identify important ₂₇₇ prognostic signatures in head and neck cancer 38 . The feature extraction presented in 38 278 was formalized as a free and open-source software 26 26 26 and has enabled transparency

and reproducibility for feature extraction, and contributed to the growing interest in $_{280}$ quantitative image analysis in many areas of medical imaging, including lung cancer ²⁸¹ screening. To date, many of the radiomic studies for pulmonary nodule assessment have $_{282}$ been performed based on relatively small data sets and with no ground-truth for nodule ₂₈₃ cancer status. Previous studies have shown that radiomic features can help identify lung ₂₈₄ cancer subtypes^{[39](#page-21-6), [40](#page-21-7)} and even the presence of therapy-targetable somatic mutations $_{285}$ (e.g., EGFR, KRAS)^{[41](#page-21-8)–[45](#page-22-0)}. The use of non-invasive image features is growing in popularity $_{286}$ and will help improve lung cancer screening program efficiency.

To our knowledge, our radiomics study is the largest study to date to systematically investigate the importance of radiomics for pulmonary nodule assessment. We 289 performed supervised, semi-automated segmentation of pulmonary nodules for three ²⁹⁰ lung cancer screening studies using an open-source tool that is available for anyone to $_{291}$ use. Our study was based on 16,797 nodules among 6,865 participants from four lung $_{292}$ cancer screening cohorts. We used a systematic approach to develop machine learning ₂₉₃ prediction model using radiomics features that were consistently predictive across each ²⁹⁴ of these four independent screening cohorts. With increasing usage of computer-aided $_{295}$ diagnositc (CAD) software, the segmentation process can be fully automated. The model ²⁹⁶ presented here can be easily implemented without additional processing need for a $_{297}$ large-amount of images with the added advantage of minimum inter-reader variability. $_{298}$

Our study has several limitations worth highlighting. First, ground-truth nodule-level ²⁹⁹ malignancy status was unavailable for two of the screening studies (NLST, PLuSS). As $\frac{300}{200}$ such, we used a set of rules to assign nodule-level malignancy status for participants with $_{301}$ a lung cancer diagnosis. Imperfect assignment will lead to missclassification errors that $_{302}$ can bias the results of our study. However, we used a relatively conservative approach $_{303}$ based on suspicion of malignancy determined by expert review of nodules by our $_{304}$ radiologist, who has extensive experience in lung CT assessment. For this reason, we ₃₀₅

believe the potential for missclassification bias is limited. There were feature extraction $\frac{306}{306}$ issues that excluded 5.7% of the candidate nodules. Nearly 80% of these issues were 307 due to very small nodules with segmentation masks containing only a single voxel or ³⁰⁸ were 1-dimensional after resampling and interpolation. These micronodules have a very $\frac{309}{200}$ low prior probability of being malignant and their exclusion are unlikely to bias our results. 310 Lastly, there was numerical instability for a small set of radiomic features when computing $\frac{311}{211}$ on derived images (i.e., after transformations). We minimized potential bias from these $\frac{312}{2}$ unstable features by excluding them for the filters where identifiable problems arose. All $_{313}$ radiomic features appeared stable based on the original image. 314

In summary, we developed a nodule assessment model based on quantitative imaging 315 and patient-level features collected from four international lung cancer screening cohorts. ³¹⁶ We believe this study contributes important insights into the role that high-dimensional 317 radiomic features can play in accurately assessing nodule malignancy risk and that 318 these features generalize well to geo-temporally distinct screening cohorts. At present, $\frac{319}{2}$ there is emerging interest in analyzing medical images using deep learning computer $\frac{320}{2}$ vision approaches, although limited transparency in model development and lack of 321 model interpretability can pose challenges for clinical implementation and widespread ₃₂₂ adoption^{[46](#page-22-1), [47](#page-22-2)}. In the future, our model may help to improve nodule malignancy 323 assessment and provide supplemental information that can help quide decision-making 324 for screen-detected nodule management. 325

References ³²⁶

11. Horeweg N, Rosmalen J van, Heuvelmans MA, et al: Lung cancer probability in 352 patients with CT-detected pulmonary nodules: A prespecified analysis of data from the 353 NELSON trial of low-dose CT screening. The Lancet Oncology 15:1332-1341, 2014 354 **12.** Oudkerk M, Devaraj A, Vliegenthart R, et al: European position statement on lung 355 cancer screening. The Lancet Oncology 18:e754–e766, 2017 **13.** Callister M, Baldwin D, Akram A, et al: British thoracic society quidelines for the 357 investigation and management of pulmonary nodules: Accredited by NICE. Thorax 358 70:ii1–ii54, 2015 ³⁵⁹ **14.** Baldwin DR, Callister ME: The british thoracic society guidelines on the investigation $\frac{360}{100}$ and management of pulmonary nodules. Thorax $70:794-798$, 2015 **15**. Yip R, Henschke CI, Yankelevitz DF, et al: CT screening for lung cancer: Alternative 362 definitions of positive test result based on the national lung screening trial and international ₃₆₃ early lung cancer action program databases. Radiology $273:591-596$, 2014 **16. NCCN practice guidelines in oncology lung cancer screening guideline version 4.2019. 365** *https://www.nccn.org/professionals/physician_gls/default.aspx* ³⁶⁶ **17.** Zhou Q, Fan Y, Wang Y, et al: Guidelines for low-dose spiral CT screening of lung 367 cancer in china (2018 edition). Zhongguo Fei Ai Za Zhi 21:67–75, 2018 **18**. Bueno J, Landeras L, Chung JH: Updated fleischner society guidelines for ³⁶⁹ managing incidental pulmonary nodules: Common questions and challenging scenarios. 370 Radiographics 38:1337–1350, 2018 371 **19.** MacMahon H, Naidich DP, Goo JM, et al: Guidelines for management of incidental 372 pulmonary nodules detected on CT images: From the fleischner society 2017. Radiology 373 **284:228–243, 2017** 374 **20**. Tammemagi MC, Lam S: Screening for lung cancer using low dose computed ³⁷⁵ tomography. Bmj 348, 2014 $\frac{376}{376}$ **21.** Lim KP, Marshall H, Tammemägi M, et al: Protocol and rationale for the international 377 lung screening trial. Annals of the American Thoracic Society 17:503–512, 2020 $\frac{378}{378}$

22. Kakinuma R, Ashizawa K, Kusunoki Y, et al: The pulmonary nodules management 379 committee of the japanese society of CT screening. Guidelines for the management of 380 pulmonary nodules detected by low-dose CT lung cancer screening version 3 **23**. Toumazis I, Bastani M, Han SS, et al: Risk-based lung cancer screening: A systematic ³⁸² review. Lung Cancer 147:154–186, 2020 383 **24**. Fox AH, Tanner NT: Approaches to lung nodule risk assessment: Clinician intuition ³⁸⁴ versus prediction models. Journal of Thoracic Disease 12:3296, 2020 385 **25**. Loverdos K, Fotiadis A, Kontogianni C, et al: Lung nodules: A comprehensive review 386 on current approach and management. Annals of Thoracic Medicine $14:226$, 2019 **26**. Van Griethuysen JJ, Fedorov A, Parmar C, et al: Computational radiomics system to ³⁸⁸ decode the radiographic phenotype. Cancer research 77:e104–e107, 2017 **27.** Tammemagi MC, Schmidt H, Martel S, et al: Participant selection for lung cancer screening by risk modelling (the pan-canadian early detection of lung cancer [PanCan] 391 study): A single-arm, prospective study. The lancet oncology 18:1523–1531, 2017 **28**. Roberts HC, Patsios D, Paul NS, et al: Lung cancer screening with low-dose computed ₃₉₃ tomography: Canadian experience. Canadian Association of Radiologists Journal 58:225, ³⁹⁴ 2007 and the set of t **29.** Menezes RJ, Roberts HC, Paul NS, et al: Lung cancer screening using low-dose $\frac{396}{2}$ computed tomography in at-risk individuals: The toronto experience. Lung Cancer 397 67:177–183, 2010 ³⁹⁸ **30.** Wilson DO, Weissfeld JL, Fuhrman CR, et al: The pittsburgh lung screening study ₃₉₉ (PLuSS) outcomes within 3 years of a first computed tomography scan. American journal ⁴⁰⁰ of respiratory and critical care medicine $178.956 - 961$, 2008 **31.** Tammemägi MC, Katki HA, Hocking WG, et al: Selection criteria for lung-cancer ₄₀₂ screening. New England Journal of Medicine 368:728–736, 2013

32. Fedorov A, Beichel R, Kalpathy-Cramer J, et al: 3D slicer as an image ⁴⁰⁴ computing platform for the quantitative imaging network. Magnetic resonance imaging ⁴⁰⁵

30:1323–1341, 2012 ⁴⁰⁶

33. San Jose Estepar R, Ross JC, Harmouche R, et al: Chest imaging platform: An 407 open-source library and workstation for quantitative chest imaging, in C66. Lung imaging ⁴⁰⁸ II: New probes and emerging technologies. American Thoracic Society, 2015, pp $_{409}$ $\mathsf{A}4975$ and $\mathsf{A}4975$ and

34. Krishnan K, Ibanez L, Turner WD, et al: An open-source toolkit for the volumetric $_{411}$ measurement of CT lung lesions. Optics Express 18:15256–15266, 2010

35. McKay MD, Beckman RJ, Conover WJ: A comparison of three methods for 413 selecting values of input variables in the analysis of output from a computer code $_{414}$ [Internet]. Technometrics 21:239–245, 1979[cited 2022 Apr 6] Available from: ⁴¹⁵ <http://www.jstor.org/stable/1268522> 416

36. Van Rossum G, Drake FL: Python 3 reference manual. Scotts Valley, CA, ⁴¹⁷ CreateSpace, 2009 418

37. R Core Team: R: A language and environment for statistical computing [Internet]. ⁴¹⁹ Vienna, Austria, R Foundation for Statistical Computing, 2021Available from: [https://ww](https://www.R-project.org/) [420](https://www.R-project.org/) [w.R-project.org/](https://www.R-project.org/) 421

38. Aerts HJ, Velazquez ER, Leijenaar RT, et al: Decoding tumour phenotype by 422 noninvasive imaging using a quantitative radiomics approach. Nature communications ₄₂₃ $5:1-9, 2014$ 424

39. Li H, Gao L, Ma H, et al: Radiomics-based features for prediction of histological 425 subtypes in central lung cancer. Frontiers in Oncology 11:1522, 2021

40. Linning E, Lu L, Li L, et al: Radiomics for classifying histological subtypes of lung 427 cancer based on multiphasic contrast-enhanced computed tomography. Journal of 428 computer assisted tomography $43:300, 2019$ $\qquad \qquad$ 429

41. Wu S, Shen G, Mao J, et al: CT radiomics in predicting EGFR mutation in non-small ⁴³⁰ cell lung cancer: A single institutional study. Frontiers in Oncology 2044, 2020 $_{431}$ **42.** Hong D, Xu K, Zhang L, et al: Radiomics signature as a predictive factor for EGFR 432

Table 1. Patient-level and nodule-level descriptive statistics for each of the four screening cohorts included in this study. Means and standard deviations are reported for numeric variables and counts and proportions are reported for categorical variables.

Abbreviations: COPD, chronic obstructive pulmonary disease; IELCAP, International Early Lung Cancer Action Plan; mm, millimeter; NLST, National Lung Screening Trial; No., number; PanCan, PanCanadian Early Detection of Lung Cancer Study; PLuSS, Pittsburgh Lung Screening Study.

Table 2. Area under the receiver operating characteristic curve (AUC) based on the Kfold cross-validation of three different machine learning classification models for nodule malignancy prediction based on epidemiologic and radiomic features. We present the cross-validated AUC and confidence intervals.

Abbreviations: AUC, area under the curve; CI, confidence interval; LASSO, least absolute shrinkage and selection operator; ML, machine learning; Num, number; XGBoost, eXtreme Gradient Boosting. ¹ The penalty parameter for the LASSO model was a L1 (i.e., LASSO) penalty.

Table 3. Comparison of sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and positive prevalence between our radiomics model and the established Brock Model. We provide point estimates and 95% percentile-based bootstrap confidence intervals for each statistic.

Abbreviations: NPV, negative predictive value; PPV, positive predictive value.

Note: Sensitivity is the proportion of malignant nodules correctly identified as malignant. Specificity is the proportion of benign nodules correctly identified as benign. PPV is the proportion of positive predictions that are malignant nodules. NPV is the proportion of negative predictions that are benign nodules. Accuracy is the total number of correct predictions out of the total number of nodules. Positive prevalence is the proportion of positive predictions divided by the total number of predictions.

¹ The radiomics model was evaluated in the 20% hold-out test data not used for model development (N = 3,363).

 2 The Brock Model was evaluated in the entire eligible set of participants from IELCAP-Toronto, NLST, and PLuSS (N = 8,622).

Figure 1. Schematic for the analytic framework used in this study. Data were partitioned into training/validation and testing splits using group-based random sampling to ensure all nodules for ^a participant were in ^a single set to avoid data leakage. Radiomic features were extracted and subject to filtering to exclude low-quality and highly-redundant features. K-fold cross-validation was performed to identify the optimal machine learning (ML) model and the optimal set of hyperparameters. The final ML model was fitted to the entire training data set and tested for out-of-sample performance in the hold-out test data; discrimination and calibration performance metrics are reported.

Figure 2. Receiver operating characteristic (ROC) curves for our radiomics models and the established Brock Model. Area under the curve (AUC) and 95% confidence intervals are reported.